Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Lyra Therapeutics

08/08/2023 23:01

* Lyra Therapeutics Inc  LYRA.OQ  reported a quarterly
adjusted
loss of 32 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 42 cents per share.
    * Revenue rose 12.5% to $458.00 thousand from a year ago;
analysts
expected $136.67 thousand. 
    * Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 36 cents​.
    * The mean earnings estimate of analysts had fallen by
about 10%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Lyra Therapeutics Inc shares had fallen by 24.1% this
quarter and lost 0.6% so far this year.
    * The company reported a quarterly loss of $15.62 million.
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $14.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.42          -0.32          Beat
 Mar. 31 2023      -0.36          -0.44          Missed
 Dec. 31 2022      -0.41          -0.38          Beat
 Sep. 30 2022      -0.44          -0.40          Beat